Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mydecine Innovations Group Inc
(OP:
MYCOF
)
0.0074
-0.0032 (-30.19%)
Streaming Delayed Price
Updated: 12:54 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mydecine Innovations Group Inc
< Previous
1
2
3
4
Next >
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Board Approves Issuance of Shares for Debt Settlement
March 21, 2024
Via
Investor Brand Network
Mydecine Innovations Group Inc. Announces Share for Debt Settlement
March 20, 2024
VANCOUVER, BC / TheNewswire / 20 March 2024 -- Mydecine Innovations Group Inc. (CSE: MYCO) (FSE: 0NFA), (OTC: MYCOF) (AQSE: MYIG) (the “Company” or “Mydecine”) announced that it has entered into a debt...
Via
TheNewswire.com
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Compounds Receive USPTO Notice of Allowances
February 08, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces USPTO Issues Notice of Allowance for MYCO-005 Compound
December 18, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Product Safety
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
December 18, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Updates Special Access Program
November 29, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Files Prospectus Supplement, Closes Share Subscription Agreements
October 31, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Reports on Company Progress in Q4 2023 Update
October 26, 2023
Via
Investor Brand Network
Exposures
Product Safety
Mydecine Provides Q4 2023 Business Update
October 26, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
Mydecine Innovations Group gearing up for human trials after completing Aquis listing
October 18, 2023
Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) CEO Joshua Bartch speaks to Thomas Warner from Proactive London about the biotechnology company's ambitious goals in the psychedelic medicine...
Via
TheNewswire.com
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Starts Trading on the AQSE Growth Market
October 10, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Product Safety
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings
October 10, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) Common Shares Begin Listing on CSE
October 06, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Expects UK Dual Listing Admission Next Month
September 28, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Receives CSE Listing Conditional Approval
August 31, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Mydecine Announces Conditional Approval of CSE Listing
August 30, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Leadership Update
July 24, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reports on Special Meeting
July 06, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Prospectus Supplement, Closes 1st Tranche of Subscription Agreement, Reappoints Board Member
May 30, 2023
Via
Investor Brand Network
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors
May 29, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Results of Annual General Shareholders Meeting
May 11, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Mydecine Reports its 2023 Annual General Shareholders' Meeting Results
May 10, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Preclinical Results on MYCO-006 Series
April 24, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
Product Safety
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues
April 24, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Closes on Share Subscription Agreement
April 20, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Filing of Prospectus Supplement, First Tranche Closing
April 11, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Issues Corporate Update
April 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Mydecine Innovations Group Provides Corporate Update
April 03, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
Mydecine Reports Financial Results for the Year Ended December 2022
March 31, 2023
From
Mydecine Innovations Group Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reports on Debt Settlement Agreements
March 06, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.